Patents Examined by Benjamin P. Blumel
-
Patent number: 11957745Abstract: The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.Type: GrantFiled: February 22, 2019Date of Patent: April 16, 2024Assignee: VANDERBILT UNIVERSITYInventor: James E. Crowe, Jr.
-
Patent number: 11952400Abstract: Provided are a bovine rotavirus fusion protein and calf diarrhea multivalent vaccine. The bovine rotavirus fusion protein contains a VP6 fragment, wherein the VP6 fragment contains an amino acid sequence as represented by SEQ ID NO. 4, and at least one loop region of the following (a)˜(c) is substituted with an antigenic epitope derived from bovine coronavirus and/or an antigenic epitope derived from E. coli: (a) amino acid residues of sites 168-177; with an amino acid sequence as represented by SEQ ID NO. 1; (b) amino acid residues of sites 194-205; with an amino acid sequence as represented by SEQ ID NO. 2; and (a) amino acid residues of sites 296-316, with an amino acid sequence as represented by SEQ ID NO. 3, The bovine rotavirus fusion protein contains a plurality of antigenic epitopes, and can enable a host to generate a plurality of antibodies after immunizing the host.Type: GrantFiled: April 16, 2021Date of Patent: April 9, 2024Assignee: TECON BIOPHARMACEUTICAL CO., LTD.Inventors: Sun He, Yiping Pan, Guoqing Zhang, Pengxian Yan, Na Xi, Miaomiao Guo, Shengdong Xiao, Tianzeng Li, Rui Han, Yumeng Wang, Jiubin Du, Pei Zheng, Jian Cao
-
Patent number: 11944679Abstract: A protocol has been developed for genetically engineering an attenuated pathogen such as the influenza virus that can grow in cells without interferons but has suppressed growth in cells with the interferons. The protocol comprises systematically identifying immune evasion functions on the pathogen's genome, then eliminating the immune evasion functions while maintaining a certain replication fitness of the pathogen. The resulting attenuated pathogen causes a strong immunologic response and can be used in a live attenuated vaccine.Type: GrantFiled: March 14, 2018Date of Patent: April 2, 2024Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Yushen Du, Nicholas C. Wu, Ren Sun
-
Patent number: 11944645Abstract: The present disclosure describes compositions and methods for treating cancer. Embodiments relate to a cell modified to express one or more molecules at a level that is higher or lower than the level of the one or more molecules expressed by a cell that has not been modified to express the one or more molecules, wherein the one or more molecules comprise Cavin3, ZBED2, and MYC.Type: GrantFiled: September 30, 2021Date of Patent: April 2, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Zhiyuan Cao, Lei Xiao, Yuzhe Peng, Wei Ding, Wensheng Wang
-
Patent number: 11938221Abstract: Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species with in the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and/or strains of infectious agents.Type: GrantFiled: November 4, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Barney S. Graham, Masaru Kanekiyo, Hadi M. Yassine
-
Patent number: 11939356Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.Type: GrantFiled: March 15, 2021Date of Patent: March 26, 2024Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Peter Kwong, Ivelin Georgiev, Michael Gordon Joyce, Masaru Kanekiyo, Aliaksandr Druz, Ulrich Baxa, Joseph Van Galen, Cheng Cheng, John Mascola, Yaroslav Tsybovsky, Yongping Yang, Barney Graham, Syed Mohammad Moin, Jeffrey Boyington
-
Patent number: 11931407Abstract: The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8+ T cell epitopes, wherein the peptide is attached to a nanoparticle.Type: GrantFiled: August 29, 2022Date of Patent: March 19, 2024Assignee: EMERGEX VACCINES HOLDING LIMITEDInventor: Ramila Philip
-
Patent number: 11932668Abstract: Provided herein are methods of selective screening. In addition, various targeting proteins and sequences, as well as methods of their use, are also provided.Type: GrantFiled: August 13, 2021Date of Patent: March 19, 2024Assignee: California Institute of TechnologyInventors: Benjamin E. Deverman, Paul H. Patterson, Viviana Gradinaru
-
Patent number: 11932682Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.Type: GrantFiled: October 21, 2021Date of Patent: March 19, 2024Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
-
Patent number: 11918637Abstract: The invention relates to compositions and methods for treating or preventing diseases caused by Porcine circoviruses. The invention particularly discloses methods for controlling PCV infection or disease in a pig herd, comprising (i) vaccinating sows against PCV at weaning, and (ii) vaccinating piglets against PCV at an age of between 2 to 7 weeks.Type: GrantFiled: June 10, 2019Date of Patent: March 5, 2024Inventor: Roman Krejci
-
Patent number: 11911465Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.Type: GrantFiled: July 22, 2021Date of Patent: February 27, 2024Assignee: PDS Biotechnology CorporationInventors: Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
-
Patent number: 11911462Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.Type: GrantFiled: July 12, 2023Date of Patent: February 27, 2024Assignee: INSTITUT PASTEURInventors: Etienne Simon-Loriere, Matthieu Prot, Xavier Montagutelli
-
Patent number: 11905517Abstract: The invention relates to recombinant Kluyveromyces lactis (K. lactis) yeasts which are capable of the highly efficient expression of one or more foreign proteins and are suitable for use as a vaccine for generating a protective immune response against pathogens. The invention provides in particular K. lactis strains for the targeted cloning of foreign antigen-coding nucleic acids into the yeast genome of the K. lactis strain, which is characterized in that the K. lactis strain has integrated expression cassettes for foreign antigens as an alternative or in addition to the KILAC4 locus on the KIURA3-20 locus (KLLA0E22771g) and/or on the KIMET5-1 locus (KLLA0B03938g). The invention further relates to integrative expression vectors and to methods for producing the K. lactis strains of the invention as well as to the use thereof as vaccines.Type: GrantFiled: December 19, 2018Date of Patent: February 20, 2024Assignee: VEROVACCINES GMBHInventors: Hans Caspar Hührlimann, Martina Behrens, Mandy Gebauer, Karin Breunig, Sven-Erik Behrens
-
Patent number: 11904015Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.Type: GrantFiled: April 18, 2019Date of Patent: February 20, 2024Assignee: PDS BIOTECHNOLOGY CORPORATIONInventors: Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
-
Patent number: 11896636Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.Type: GrantFiled: July 6, 2012Date of Patent: February 13, 2024Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Andrew Geall, Ethan Settembre
-
Patent number: 11896665Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.Type: GrantFiled: April 9, 2021Date of Patent: February 13, 2024Assignee: The Council of the Queensland Institute of Medical ResearchInventors: Rajiv Khanna, Dasari Vijayendra
-
Patent number: 11897918Abstract: Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.Type: GrantFiled: March 11, 2019Date of Patent: February 13, 2024Assignee: Seqirus UK LimitedInventors: Samuel Ho, David Parker, Peter Fekkes, Ivna De Souza, Peter Mason, Pirada Allen
-
Patent number: 11891630Abstract: The present disclosure provides methods of generating recombinant bacteriophage genomes via semi-synthesis. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a bacteriophage genome, and isolating recombinant bacteriophages that express the heterologous nucleic acid sequence.Type: GrantFiled: August 7, 2018Date of Patent: February 6, 2024Inventors: Kirsty A. McFarland, Miles T. Rogers, Connor McBrine, Jason W. Holder
-
Patent number: 11890338Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.Type: GrantFiled: September 26, 2019Date of Patent: February 6, 2024Assignees: DENKA COMPANY LIMITED, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITYInventors: Ryotaro Mitsumata, Shogo Misumi, Naoki Kishimoto, Takuma Gotanda, Nagisa Nakata
-
Patent number: 11883483Abstract: The present invention relates to a method of preparing an influenza working virus seed stock, a method of increasing infectivity of an influenza working virus seed stock, a method of preparing an influenza vaccine using the seed stock, an influenza vaccine prepared by the method, and an influenza working virus seed stock having increased infectivity.Type: GrantFiled: July 5, 2018Date of Patent: January 30, 2024Assignee: SK BIOSCIENCE CO., LTD.Inventors: Yun Hee Kim, Yong Wook Park, Dong Soo Ham, Hwan Ui Jung, Hun Kim